Open Access4CPS-181 Study of the reasons for the therapeutic discontinuation of immune-based therapies in relapsing-remitting multiple sclerosis
Author(s) -
S Marín Rubio,
M Miarons Font,
Lourdes Cordón,
A Sánchez Ulayar,
L Campins Bernadàs,
C Agustí Maragall,
M Camps Ferrer,
T Gurrera Roig,
D López Faixó
Publication year - 2018
Publication title -
section 4: clinical pharmacy services
Language(s) - English
Resource type - Conference proceedings
DOI - 10.1136/ejhpharm-2018-eahpconf.271
Subject(s) - fingolimod , medicine , natalizumab , glatiramer acetate , multiple sclerosis , discontinuation , teriflunomide , adverse effect , drug , pharmacology , immunology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom